Finch Therapeutics appoints Matthew Blischak CEO
PremiumThe FlyFinch Therapeutics appoints Matthew Blischak CEO
1y ago
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
Premium
The Fly
Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
1y ago
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Premium
Press Releases
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
1y ago
Oppenheimer emerging biotech analyst to hold analyst/industry conference call
PremiumThe FlyOppenheimer emerging biotech analyst to hold analyst/industry conference call
2y ago
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Premium
Press Releases
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
2y ago
Finch Therapeutics to reduce workforce by 95%
Premium
The Fly
Finch Therapeutics to reduce workforce by 95%
2y ago
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
PremiumPress ReleasesFinch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Premium
Press Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Premium
Press Releases
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100